C&Pharm's Injection Maintains IC100 for 24 Hours with Single Dose... "One Shot Could Cure COVID-19 Completely"

[Asia Economy Reporter Yoo Hyun-seok] Hyundai Bio announced on the 19th that it has become the first in the world to successfully sustain the 'blood effective concentration that suppresses virus activity by 100%' (IC100) for over 24 hours with a single dose of 'Poly-COV01,' an injectable drug developed by its major shareholder C&Pharm for severe COVID-19 patients.

Poly-COV01, made by combining the antiparasitic drug niclosamide with C&Pharm's world-class proprietary drug delivery system (DDS), also features sustained-release properties that continuously release the drug loaded in the delivery system into the bloodstream. Hyundai Bio explained that by adjusting the dosage, the possibility of curing severe COVID-19 patients with a single injection has significantly increased.

According to C&Pharm, in recent animal experiments conducted by the contract research organization (CRO) Notus, Poly-COV01 maintained a concentration above IC100 in the bloodstream for over 24 hours at a dose of 2mg/kg, and it was confirmed that the drug was continuously released from the delivery system during this period.

The company stated that there have been no official reports domestically or internationally of an intravenous injection drug like Poly-COV01 that maintains niclosamide's IC100 concentration in the blood for more than 24 hours while also achieving sustained release.

Accordingly, C&Pharm has decided to begin clinical preparations for Poly-COV01, developed as a drug for severe patients based on niclosamide. Niclosamide has recently attracted international attention as a promising COVID-19 treatment candidate, with numerous research papers and experimental results published domestically and abroad demonstrating its excellent therapeutic efficacy against COVID-19.

The world-renowned scientific journal Nature recently published a paper by European researchers who identified niclosamide as the top drug capable of preventing lung damage caused by COVID-19 infection, introducing the mechanism by which niclosamide blocks the formation of cell syncytia that cause lung damage.

A C&Pharm official said, "We succeeded in this experiment because we dramatically improved the low bioavailability and short half-life of niclosamide in the bloodstream by utilizing our proprietary delivery system technology," adding, "Following oral formulations, we plan to conduct various antiviral efficacy experiments for the injectable formulation in preparation for clinical trials."

C&Pharm's drug delivery system is based on the original technology developed by Professor Chinho Choi of Dankook University and the late Professor Yeonsu Son of Ewha Womans University. The technology was introduced in Nature in 2001 and has been published in several SCI (Science Citation Index) level papers over the past 20 years.